Ronald Eastman

Mr. Eastman has over 30 years of experience in building healthcare businesses. He began his career at American Cyanamid Company which was acquired by American Home Products (now Pfizer). At Cyanamid, Mr. Eastman spent 15 years managing various pharmaceutical products, divisions and subsidiaries in the U.S. and overseas. Since then he has helped build three private healthcare companies — Geron Corporation, HCORP and Rinat Neuroscience. Under his leadership, Geron became a cutting edge biotech company that grew from a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer. HCORP quickly established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services and was sold to a diversified competitor. Most recently, at Rinat Neuroscience, a private biotech company spun out of Genentech in late 2001, Mr. Eastman led the effort to recruit an experienced management team and move Rinat's first product for the treatment of pain into clinical trials. Rinat was acquired by Pfizer in April, 2006. Mr. Eastman joined Essex Woodlands in October 2006. He serves as Chairman of the Board of Directors at Elusys Therapeutics and on the board of directors at Revance Therapeutics, both publicly listed companies, and also serves on the Boards of OMT and IntegenX. He has served on the Board at The Buck Institute, the largest non-profit research institute in the U.S. studying diseases of aging. Mr. Eastman earned a B.A. from Williams College and an M.B.A. from Columbia University.